Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.

NCT06328179 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；

Sponsor

Huai'an First People's Hospital

Collaborators

[object Object]
[object Object]
[object Object]